Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and 'influenza-like-illness' (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need. Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed Series A and B rounds totaling $4.75M from a syndicate of Angel Investors. The company has applied for and received an SBIR(NIH) and QTDP competitive grant. Gemmus' investigational new drug (IND) application for the treatment of influenza infections was accepted by the FDA in April 2015. Gemmus plans to start clinical trials in Q2 2015.